Familial hypercholesterolaemia: identification and management

or a fibrate in addition to initial statin therapy should be taken by a specialist with expertise in FH. [2008, amended 2017] 1.3.1.16 Healthcare professionals should exercise caution when adding a fibrate to a statin because of the risk of muscle-related side effects (including rhabdomyolysis). Gemfibrozil and statins should not be used together. [2008, amended 2017] Children and young people 1.3.1.17 Healthcare professionals should offer all children and young people diagnosed with, or being investigated for, a diagnosis of FH a referral to a specialist with expertise in FH in children and young people. This should be in an appropriate child and young person-focused setting that meets the standards within the National service framework for children, young people and maternity services. [2008] 1.3.1.18 Lipid-modifying drug therapy for a child or young person with FH should usually be considered by the age of 10 years. The decision to defer or offer lipid- modifying drug therapy for a child or young person should take into account: • their age • the age of onset of coronary heart disease within the family, and • the presence of other cardiovascular risk factors, including their LDL-C concentration. [2008] 1.3.1.19 When offering lipid-modifying drug therapy for
